NEW YORK (GenomeWeb News) – Epic Sciences, which is developing diagnostics to identify and characterize rare cells, said today it is collaborating with six drug manufacturers to develop companion diagnostic tools.

The San Diego-based company declined to identify its drug manufacturer partners, but Genentech, Pfizer, and Celgene have previously disclosed working relationships with Epic.

A company spokesperson declined to elaborate on the nature of the work being done but said that targeted cancers include breast, lung, prostate, pancreatic, and ovarian cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.